Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory CLL or SLL after at least two prior treatment lines, including a BTK inhibitor and a BCL-2 inhibitor.
LAMPGEN ANALYSIS
Why it matters
The label added a CD19 CAR T option after exposure to both major targeted drug classes.
What research teams should watch
Identify patients early enough for cell collection and record the reasons and dates for discontinuing prior targeted treatments.
PRIMARY RECORDS